Q4 25 EPS
$2.12
Q4 25 Revenue
$15.50B
BEAT +1.26%
Est. $15.31B
vs S&P Since Q4 25
-5.9%
TRAILING MARKET
AZN -1.8% vs S&P +4.1%
Full Year 2025 Results
FY 25 EPS
$9.16
BEAT +99.72%
Est. $4.59
FY 25 Revenue
$58.74B
BEAT +0.33%
Est. $58.55B
Market Reaction
Did AZN Beat Earnings? Q4 2025 Results
AstraZeneca closed out 2025 with a steady fourth quarter, posting revenue of $15.50 billion, up 4.1% year-over-year and edging past the consensus estimate of $15.31 billion by 1.26%, while Q4 core EPS came in at $2.12. The headline numbers were solid… Read more AstraZeneca closed out 2025 with a steady fourth quarter, posting revenue of $15.50 billion, up 4.1% year-over-year and edging past the consensus estimate of $15.31 billion by 1.26%, while Q4 core EPS came in at $2.12. The headline numbers were solid if unspectacular, with oncology once again serving as the primary growth engine; full-year oncology revenue reached $25.62 billion, growing 15%, led by Imfinzi's 29% surge to $6.06 billion and Enhertu's 40% climb to $2.77 billion. Gross margin narrowed by 2 percentage points to 80% in the quarter, weighed down by $235.00 million in royalty buyout costs for Saphnelo and rilvegostomig, a reminder that pipeline investment carries near-term costs. CEO Pascal Soriot, whose 2025 compensation rose 6% to approximately $23.87 million reflecting the company's strong full-year performance, faces a demanding 2026 agenda, with management guiding for mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant exchange rates, supported by more than 20 Phase 3 readouts anticipated during the year.
Key Takeaways
- • Oncology therapy area growth driven by Imfinzi new indications in bladder and lung cancer, Enhertu HER2-low breast cancer uptake, and Truqap rapid market share gains
- • Farxiga growth driven by heart failure and CKD indications supported by SGLT2 class cardiorenal guidelines
- • Tezspire 65% growth from sustained severe asthma demand with launch momentum across multiple markets
- • Ultomiris 20% growth from patient demand including naïve-to-branded and conversion from Soliris
- • 16 blockbuster medicines now generating over $1 billion annual revenue each
- • Growth across all major geographic regions with Emerging Markets ex-China up 19%
AZN YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
AZN Revenue by Segment
With YoY comparisons, source: SEC Filings
AZN Revenue by Geography
With YoY comparisons, source: SEC Filings
“In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines.”
— Pascal Soriot, Q4 2025 Earnings Press Release
AZN Earnings Trends
AZN vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
AZN EPS Trend
Earnings per share: estimate vs actual
AZN Revenue Trend
Quarterly revenue: estimate vs actual
AZN Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.58 | — | $15.29B | — |
| Q4 25 FY | — | $2.12 | — | $15.50B | +1.26% |
| FY Full Year | $4.59 | $9.16 | +99.72% | $58.74B | +0.33% |
| Q3 25 FY | — | $2.38 | — | $15.19B | — |
| FY Full Year | $4.59 | — | — | — | — |
| Q1 25 | — | $2.49 | — | $13.59B | — |
| Q4 24 FY | — | $2.09 | — | $14.89B | — |
| FY Full Year | — | $8.21 | — | $54.07B | — |